Cargando…

Characterization of US Food and Drug Administration Class I Recalls from 2018 to 2022 for Moderate- and High-Risk Medical Devices: A Cross-Sectional Study

BACKGROUND: Medical device recalls are initiated in response to safety concerns. Class I (highest severity) recalls imply a reasonable likelihood of serious adverse events or death associated with device use. Recalled devices must be identified, assessed, and corrected or removed, upon which a recal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mooghali, Maryam, Ross, Joseph S, Kadakia, Kushal T, Dhruva, Sanket S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204764/ https://www.ncbi.nlm.nih.gov/pubmed/37229515 http://dx.doi.org/10.2147/MDER.S412802

Ejemplares similares

Medical device risk (re)classification: lessons from the FDA’s 515 Program Initiative
por: Mooghali, Maryam, et al.
Publicado: (2023)

Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis
por: Wallach, Joshua D., et al.
Publicado: (2019)

Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments
por: Skydel, Joshua J., et al.
Publicado: (2019)

An Analysis of Foot and Ankle Device Recalls by the Food and Drug Administration
por: Pellerin, Carl, et al.
Publicado: (2018)

Trends in Within-Class Changes in US Average Wholesale Prices for Brand-Name Medications for Common Conditions From 2015 to 2020
por: Liu, Patrick, et al.
Publicado: (2021)

Risk of Recall Associated With Modifications to High-risk Medical Devices Approved Through US Food and Drug Administration Supplements
por: Dubin, Jonathan R., et al.
Publicado: (2023)

Market competition among manufacturers of novel high-risk therapeutic devices receiving FDA premarket approval between 2001 and 2018
por: Rathi, Vinay K, et al.
Publicado: (2023)

Feasibility of Using Real-world Data to Emulate Postapproval Confirmatory Clinical Trials of Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval
por: Wallach, Joshua D., et al.
Publicado: (2021)

Financial conflicts of interest among US physician authors of 2020 clinical practice guidelines: a cross-sectional study
por: Mooghali, Maryam, et al.
Publicado: (2023)

Risk of Recall Among Medical Devices Undergoing US Food and Drug Administration 510(k) Clearance and Premarket Approval, 2008-2017
por: Dubin, Jonathan R., et al.
Publicado: (2021)

Analysis of 408 Total Ankle Arthroplasty Adverse Events Reported to the US Food and Drug Administration from 2015-2018
por: Chen, Jie, et al.
Publicado: (2020)

Adverse Events Involving Hallux Metatarsophalangeal Joint Implants: Comprehensive Analysis of US Food and Drug Administration Data from 2010 to 2018
por: Akoh, Craig C., et al.
Publicado: (2020)

Review of Evidence Supporting 2022 US Food and Drug Administration Drug Approvals
por: Kaplan, Robert M., et al.
Publicado: (2023)

Medical Device Regulation: Time to Improve Performance
por: Dhruva, Sanket S., et al.
Publicado: (2012)

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022
por: Kayki-Mutlu, Gizem, et al.
Publicado: (2023)

Use of Mechanical Cardiopulmonary Resuscitation Devices for Out-of-Hospital Cardiac Arrest, 2010-2016
por: Kahn, Peter A., et al.
Publicado: (2019)

Regarding Combined Pediatric and Adult Trials Submitted to the US Food and Drug Administration 2012–2018
por: Cook, Jack, et al.
Publicado: (2020)

Comparison of Duration of Postapproval vs Pivotal Trials for Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval, 2009-2018
por: Wallach, Joshua D., et al.
Publicado: (2021)

Xylazine in Drug Seizure Reports and Overdose Deaths in the US, 2018–2022
por: Cano, Manuel, et al.
Publicado: (2023)

In Vitro‐to‐In Vivo Extrapolation of Transporter Inhibition Data for Drugs Approved by the US Food and Drug Administration in 2018
por: Yu, Jingjing, et al.
Publicado: (2020)

US Food and Drug Administration Accelerated Approval Program for Nononcology Drug Indications Between 1992 and 2018
por: Omae, Kenji, et al.
Publicado: (2022)

Exploring unique device identifier implementation and use for real-world evidence: a mixed-methods study with NESTcc health system network collaborators
por: Dhruva, Sanket S., et al.
Publicado: (2023)

Spillover effects of food recalls: A milk recall scenario experiment in China
por: Hao, Na, et al.
Publicado: (2022)

Characteristics of Recent Generic Drug Approvals by the US Food and Drug Administration
por: Jiao, Kuo, et al.
Publicado: (2019)

Cardiac implantable device recalls: consequences, and management
por: El-Chami, Mikhael F.
Publicado: (2021)

Recall of substandard medicines in Brazil during the period 2010–2018
por: Oliveira, Cristiani Lopes Capistrano Gonçalves, et al.
Publicado: (2023)

Postmarketing safety of orphan drugs: a longitudinal analysis of the US Food and Drug Administration database between 1999 and 2018
por: Fan, Min, et al.
Publicado: (2022)

Trends in COVID-19-related Medication Use in US Nursing Homes, 2018-2022
por: Zhang, Yuan, et al.
Publicado: (2023)

Evidence supporting FDA approval and CMS national coverage determinations for novel medical products, 2005 through 2016: A cross-sectional study
por: Roginiel, Aliya C., et al.
Publicado: (2018)

Coverage of Novel Therapeutic Agents by Medicare Prescription Drug Plans Following FDA Approval
por: Shaw, Daniel L., et al.
Publicado: (2018)

Cyberpharmacies and the role of the US Food And Drug Administration
por: Henney, Jane E
Publicado: (2001)

The US Food and Drug Administration’s Intersection with Dermatology
por: Luke, Markham C.
Publicado: (2022)

899. Epidemiology of the 2022 Mpox Outbreak in the US Veterans Health Administration (VHA)
por: Lucero-Obusan, Cynthia A, et al.
Publicado: (2023)

GLASS(Y) Half-Full: Moving Towards Greater Pragmatism in Outcome Ascertainment for Clinical Trials
por: Dhruva, Sanket S.
Publicado: (2021)

Physical activity, patient-reported symptoms, and clinical events: Insights into postprocedural recovery from personal digital devices
por: Bartlett, Victoria L., et al.
Publicado: (2021)

A Hazard Analysis of Class I Recalls of Infusion Pumps
por: Gao, Xuemei, et al.
Publicado: (2019)

The Moderating Role of Emotion Regulation in the Recall of Negative Autobiographical Memories
por: Colombo, Desirée, et al.
Publicado: (2021)

Use of Expedited Regulatory Programs and Clinical Development Times for FDA-Approved Novel Therapeutics
por: Wong, Alissa K., et al.
Publicado: (2023)

Perspectives in managing recalls of cardiac implantable electronic devices
por: Varma, Niraj
Publicado: (2016)

Identification of US-pharmaceutical patents expiring between 2018 and 2022 and their effect on the Brazilian domestic market
por: Paes, Thalita D.M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_r77pqcvolc9uu0trh19lvddkoh